Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29583284 | 0.99 | CRBN (0.48) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26691519 | 0.99 | CRBN (0.48) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL29583097 | 0.96 | CRBN (0.51) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL23541282 | 0.96 | CRBN (0.51) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL29610888 | 0.89 | IKZF2 (0.60) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL24315904 | 0.89 | IKZF2 (0.60) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL26597810 | 0.89 | CRBN (0.47) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL24329413 | 0.87 | CRBN (0.46) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL24329455 | 0.87 | DDB1 (0.47) | CRBNDDB1IKZF2IKZF3ALDH1A1 | |
| SCHEMBL29584464 | 0.87 | DDB1 (0.47) | CRBNDDB1IKZF2IKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006783-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006753-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | CRBN 1/4885DDB1 165/4885IKZF2 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.